NCT04745910 2025-12-18
Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
M.D. Anderson Cancer Center
Phase 4 Active not recruiting
Clinical Trials
9 trialsNCT01564277 2018-01-09
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00057811 2014-09-19
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Children's Oncology Group
Phase 2 Completed
NCT00664144 2012-03-07
GRAAL2
Sanofi
Phase 2 Terminated
NCT00230178 2010-01-12
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
Sanofi
Phase 3 Completed
NCT00631579 2009-10-02
Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma
Sanofi
Phase 2 Completed
NCT00230217 2009-03-30
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
Sanofi
Phase 4 Completed
NCT00290992 2009-03-30
Rasburicase for Hyperuricemia
Sanofi
Phase 2 Completed
NCT00651911 2008-04-03
Fasturtec TLS Treatment / Prophylysis
Sanofi
Phase 4 Completed